HC Wainwright Rates AgomAb Therapeutics (AGMB) buy

HC Wainwright reaffirmed its buy rating on AGMB with a $35 price target, a 218.76% upside from the current price.

By EarningsIQ Research Desk · Published Jun 22, 2026, 8:01 AM EDT · Updated Jun 22, 2026, 9:06 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated AgomAb Therapeutics NV ($AGMB) "buy" with a $35 price target on June 22, 2026.

Since the rating, $AGMB is up 50.5% after 1 week, down 2.0% after 1 month and down 30.1% to date (from the $11.84 close on Jun 22, 2026).

AGMB AgomAb Therapeutics NV

$8.28 -32.79% past 3 months

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating on AGMB with a price target of $35 on June 22, 2026.
HC Wainwright's $35 price target implies 218.76% upside from AgomAb Therapeutics NV's ($AGMB) current $10.98 share price.
Shares of AGMB traded at $10.98 on Monday, reflecting investor interest following the analyst rating.
Other analysts, including Leerink Partners and JP Morgan, also initiated buy ratings earlier this year.

Get $AGMB trade alerts by text

We text you when insiders, Congress or big funds trade $AGMB. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated AgomAb Therapeutics NV alert may contain errors. Disclosures

HC Wainwright reaffirmed its positive outlook on AGMB by reiterating a buy rating and setting a price target of $35. This update came on June 22, 2026, with analyst Patrick R. Trucchio providing the insights. The reiteration suggests confidence in AGMB's potential upside.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +49.04% hypothetical

All-time return +148.12% S&P 500 +29.05%

vs. S&P 500 +119.07% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

On June 22, 2026, HC Wainwright & Co. reiterated its buy rating on AGMB, maintaining a price target of $35. Earlier this year, on March 3, 2026, Leerink Partners and JP Morgan both initiated buy ratings with targets of $36 and $32, respectively. Morgan Stanley also joined in with a buy rating and a $28 target. These consistent buy ratings indicate a strong consensus among analysts about AGMB's potential.

Other Institutional Activity in AGMB

In recent institutional activity, TCG Crossover Management, LLC opened a new position in AGMB, acquiring 2,053,233 shares valued at approximately $21.5 million. This move highlights growing institutional interest in the company.

AgomAb Therapeutics NV Stock Down 9.8%

Shares of AGMB traded at $10.98 on Monday. The stock's performance and the reiterated buy ratings suggest optimism in the market. While specific fundamental metrics for AGMB are not provided, the analyst ratings and recent institutional investments reflect a positive sentiment.

12-month forecast

$AGMB price target

AgomAb Therapeutics NV daily closes and this analyst's $35 target. Not advice.

Bottom Line

AGMB is attracting attention from both analysts and institutional investors. HC Wainwright's reiterated buy rating with a $35 target underscores this confidence. While the 13F filings and analyst updates provide historical data, they highlight the continued interest in AGMB's growth potential.